NONPRESCRIPTION DRUGS ADVISORY COMMITTEE
October 19, 2000
Safety Issues of Phenylpropanolamine (PPA) in Over-the-Counter Drug Products
OPEN PUBLIC HEARING
Brian Strom, M.D., MPH, University of Pennsylvania representing Whitehall Corporation ppt htm
Statement on Phenylpropanolomine, David E. Schteingart, M.D., University of Michigan representing Chattem doc pdf
Statement of Sidney Wolfe, M.D., Director, Public Citizen’s Health Research Group doc pdf
FDA PRESENTATIONS
Regulatory History of OTC Phenylpropanolamine Hydrochloride, Robert L. Sherman, DOTCDP ppt htm
Epidemiological Consult on the Yale Study and Recommendations to OTC Division, Lois La Grenade, M.D., M.P.H., Office of Postmarketing Drug Risk Assessment ppt htm
Summary of Issues, Charles Ganley, M.D., Director, DOTCDP ppt htm
YALE
Final Report of the Yale Hemorrhagic Stroke Project, Walter Kernan, M.D., School of Medicine, Yale pdf
COMMENTS ON THE YALE STUDY BY THE CONSUMER HEALTHCARE PRODUCTS ASSOCIATION
R. William Soller, Ph.D., Senior Vice President and Director of Science and Technology CHPA ppt htm
Noel S. Weiss, M.D., Dr. P.H., University of Washington pdf
PPA and the Risk of Hemorrhagic Stroke, Lewis H Kuller, MD
DrPH, MPH, University of
Pittsburgh School of Health pdf
Robert B Wallace, MD, University of Iowa College of Public Health and Medicine pdf
Philip B Gorelick MD MPH FACP, Rush Medical College pdf